Payment overview · 2025
General Payments
$1,172.07
25 reported records · 10 companies
Healthcare provider profile · identity verified
Bryan David Blake, MD
Allopathic & Osteopathic Physicians|Family Medicine · LITHIA SPRINGS, GA · NPI 1316930118
Verified facts
What the public records show
CMS Open Payments records show Bryan David Blake, MD received $1,172.07 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 48.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $570.43 | 48.7% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $364.43 | 31.1% | 5 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.53 | 4.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.01 | 3.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $39.61 | 3.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.47 | 2.7% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $20.02 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.51 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.46 | 1.5% | 1 | 2025 |
| Atland Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $13.60 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,172.07 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $364.43 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $266.14 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $154.03 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $129.59 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $44.01 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $39.61 | 2 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| EDARBYCLOR Normalized: edarbyclor |
Drug | Azurity Pharmaceuticals, Inc. | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE Normalized: orphenadrine citrate aspirin and caffeine |
Drug | Atland Pharmaceuticals, LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| TOLMETIN SODIUM Normalized: tolmetin sodium |
Drug | Atland Pharmaceuticals, LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 107 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
107 | 30 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 316 | 96 |
| Zolpidem Tartrate | Zolpidem Tartrate | 209 | 28 |
| Alprazolam | Alprazolam | 154 | 18 |
| Pregabalin | Pregabalin | 139 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 12 |
| Losartan Potassium | Losartan Potassium | 125 | 35 |
| Farxiga | Dapagliflozin Propanediol | 107 | 30 |
| Omeprazole | Omeprazole | 95 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 79 | 13 |
| Famotidine | Famotidine | 75 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 22 |
| Carvedilol | Carvedilol | 65 | 17 |
| Jardiance | Empagliflozin | 61 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 16 |
| Simvastatin | Simvastatin | 61 | 14 |
| Lisinopril | Lisinopril | 60 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 13 |
| Gabapentin | Gabapentin | 59 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | suppressed |
| Metformin Hcl | Metformin Hcl | 56 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 20 |
| Levothyroxine Sodium | Levothyroxine Sodium | 52 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | 13 |
| Meloxicam | Meloxicam | 45 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 15 |
| Trazodone Hcl | Trazodone Hcl | 43 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 42 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 11 |
| Donepezil Hcl | Donepezil Hcl | 37 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Baclofen | Baclofen | 34 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 13 |
| Furosemide | Furosemide | 34 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 11 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Eliquis | Apixaban | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | 12 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Kerendia | Finerenone | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Belbuca | Buprenorphine Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,172.07 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AZMIRO, BREZTRI, CRYSVITA, Cologuard Collection Kit, EDARBI, EDARBYCLOR, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE, TOLMETIN SODIUM, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error